The logo of Matica Biotechnology
By Nam Hyun-woo
Matica Biotechnology, a U.S.-based contract development and manufacturing organization (CDMO) subsidiary of Korea’s CHA Biotech, clinched a contract manufacturing deal for pediatric brain tumor therapy from Trevior.
According to Matica Biotechnology, the two sides signed a partnership agreement on producing herpes simplex virus (HSV) vectors for Trevior’s G207 HSV-based oncolytic therapy.
The therapy is currently in Phase 2 clinical trials involving 30 pediatric brain tumor patients, with the goal of confirming safety, immune response, radiation response and other indicators.
The therapy was designated as an orphan drug in the United States and Europe and granted a fast-track designation from the U.S. Food and Drug Administration.
“Finding a CDMO partner who truly understands our mission and works alongside us as an extension of our team is essential for successful drug development,” said Michael Christini, CEO of Treovir. “We are collaborating with Matica Bio on process optimization and production for G207, and we look forward to advancing this promising therapy for pediatric brain tumors, with Matica Bio playing a key role.”
Matica Biotechnology was established by CHA Biotech as part of the health care group’s bid to enter the U.S. cell and gene therapy CDMO market. In 2022, Matica Biotechnology became the first biotech from Korea to set up a CDMO facility in Texas.
“We are thrilled to partner with Treovir in this important effort,” Matica Biotechnology CEO Paul Kim said. “Pediatric rare diseases represent an area of critical need, and Matica Bio is proud to contribute to the mission of improving the lives of these children.”
English (United States)